

BC Cancer Protocol Summary for Treatment of Non-Hodgkin Lymphoma with Bendamustine

Protocol Code

LYBEND

Tumour Group

Lymphoma

Contact Physician

Dr Laurie H. Sehn

ELIGIBILITY:

Patients must have:

- Relapsed or refractory indolent non-Hodgkin lymphoma (follicular, marginal zone, lymphoplasmacytic) or
- Mantle cell lymphoma and
- Advanced stage symptomatic disease requiring therapy

EXCLUSIONS:

Patients must not have:

- Hodgkin's lymphoma or diffuse large B-cell lymphoma

CAUTION:

- Creatinine clearance CrCl less than 40 mL/min
- AST or ALT greater than 2.5 x upper limit of normal and total bilirubin greater than 1.5 x upper limit of normal

TESTS:

- Baseline, then as indicated:
 - Required before first treatment: CBC & diff, creatinine, ALT, [total](#) bilirubin
 - Required, but results do not have to be available to proceed with first treatment; results must be checked before proceeding with cycle 2: HBsAg, [HBsAb](#), HBcoreAb
- Before day 1 of each treatment cycle: CBC & diff, platelets
- If clinically indicated: creatinine, ALT, [total](#) bilirubin
- [If clinically indicated: HBV viral load \(see protocol \[SCHBV\]\(#\)\)](#)

PREMEDICATIONS:

Antiemetic protocol for moderately emetogenic chemotherapy (see protocol SCNAUSEA)

SUPPORTIVE MEDICATIONS:

[Moderate risk of hepatitis B reactivation](#). If HBsAg or HBcoreAb positive, [follow hepatitis B prophylaxis as per \[SCHBV\]\(#\)](#).

TREATMENT:

Drug	Dose	BC Cancer Administration Guideline
bendamustine	90 mg/m ² * on days 1 and 2	IV in 250 to 500 mL NS over 1 hour

* May escalate dose to 120 mg/m²

Repeat every 28 days. Maximum 6 cycles. Discontinue if definite progression at any time.

DOSE MODIFICATIONS:

1. Hematological, day 1 only

ANC (x10 ⁹ /L)		Platelets (x10 ⁹ /L)	Bendamustine
greater than or equal to 1.0	and	greater than or equal to 75	100%
less than 1.0	or	less than 75	Delay until recovery

PRECAUTIONS:

- Neutropenia:** Fever or other evidence of infection must be assessed promptly and treated aggressively.
- Thrombocytopenia:** Support with platelet transfusion may be required.
- Hepatitis B Reactivation:** See [SCHBV protocol](#) for more details.
- Infusion Reactions and Hypersensitivity:** Bendamustine can cause allergic type reactions during the IV infusion such as fever, chills, pruritus and rash. Severe anaphylactic and anaphylactoid reactions have occurred rarely, particularly in the second and subsequent cycles of therapy. If an allergic reaction occurs, stop the infusion and the physician in charge should determine a safe time and rate to resume the infusion. Consider pre-treatment with antihistamines, antipyretics and corticosteroids for patients experiencing Grade 1 or 2 infusion reactions; consider discontinuing treatment for patients experiencing Grade 3 or 4 infusion reactions. See BC Cancer Hypersensitivity Guidelines.
- Tumour Lysis Syndrome:** Tumor lysis syndrome has been associated with bendamustine, possibly leading to acute renal failure and death. Usual onset occurs during the first cycle. Maintain adequate volume status and monitor blood chemistry, including potassium and uric acid levels. Allopurinol has been used, but the concomitant use of bendamustine and allopurinol can cause increased risk of severe skin toxicity.
- Drug Interactions:** CYP1A2 inhibitors can potentially decrease plasma concentration of bendamustine. CYP1A2 inducers can potentially increase plasma concentration of bendamustine.
- Skin Reactions:** Rash, toxic skin reactions and bullous exanthema have been reported. They may be progressive and increase in severity with further treatment. Monitor closely. If skin reactions are severe or progressive, consider withholding or discontinuing bendamustine.

Call Dr. Laurie Sehn or tumor group delegate at (604) 877-6000 or 1-800-663-3333 with any problems or questions regarding this treatment program.

References:

1. Rummel MJ, et al. Bendamustine plus rituximab versus fludarabine plus rituximab in patients with relapsed follicular, indolent and mantle cell lymphomas - final results of the randomized phase III study NHL 2-2003 on behalf of the STIL (study group indolent lymphomas, Germany). *Blood*. 2010;116(21):abstr 856.
2. Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study. *Cancer* 2010; 116:106-14.
3. Cheson BD, Wendtner CM, Pieper A, et al. Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. *Clin Lymphoma Myeloma Leuk* 2010;10:21-7.